<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05627648</url>
  </required_header>
  <id_info>
    <org_study_id>KP-100-FD001</org_study_id>
    <nct_id>NCT05627648</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Confirmatory Study For Intracordal Administration Of KP-100LI In Patients With Vocal Fold Scar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kringle Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kringle Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the efficacy and safety of KP-100LI, a intracordal&#xD;
      formulation containing recombinant human dHGF as the active pharmaceutical ingredient, for&#xD;
      voice function improvement therapy in patients with vocal fold scar (including vocal fold&#xD;
      sulcus).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 18, 2022</start_date>
  <completion_date type="Anticipated">November 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement rate in Voice Handicap Index-10 (VHI-10) score at 24 weeks of the observational period</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement rate in VHI-10 score from just before the first administration (&quot;baseline&quot; at 0 week) to 4, 8, and 12 weeks of the observational period</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in VHI-10 score from baseline to 4, 8, 12, and 24 weeks of the observational period</measure>
    <time_frame>up to 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Normalized Mucosal Wave Amplitude (NMWA) from baseline to on 4, 8, 12, and 24 weeks of the observational period</measure>
    <time_frame>up to 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in GRBAS (Grade, Roughness, Breathiness, Asthenia, Strain) scale from baseline to on 4, 8, 12, and 24 weeks of the observational period</measure>
    <time_frame>up to 54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of adverse events</measure>
    <time_frame>up to 54 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Vocal Fold Scar</condition>
  <arm_group>
    <arm_group_label>KP-100LI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intracordal injection, 20 mcg once per week, 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intracordal injection, once per week, 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KP-100LI</intervention_name>
    <description>Intracordal injection, 20 mcg once per week, 3 weeks</description>
    <arm_group_label>KP-100LI</arm_group_label>
    <other_name>Hepatocyte Growth Factor</other_name>
    <other_name>HGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intracordal injection, once per week, 3 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years to 75 years&#xD;
&#xD;
          2. Presence of bilateral vocal fold scar or sulcus diagnosed&#xD;
&#xD;
          3. No other vocal lesion or vocal movement disorder&#xD;
&#xD;
          4. Voice Handicap Index-10 (VHI-10) score of 11 or higher&#xD;
&#xD;
          5. No laryngoplasty, collagen or lipid infusion to vocal cord, removal scar, fascial&#xD;
             graft, or administration of steroid or hyaluronic acid to vocal cord&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No movement disorders of the vocal fold including paralysis&#xD;
&#xD;
          2. Airway disease caused by burn&#xD;
&#xD;
          3. History of malignant tumor&#xD;
&#xD;
          4. History of allergy to local anesthesia agent&#xD;
&#xD;
          5. With impaired coagulation-fibrinolysis, or taking anticoagulant or antiplatelet drugs&#xD;
&#xD;
          6. Serious concomitant disease&#xD;
&#xD;
          7. Pregnant (including suspected), nursing, wishing to become pregnant, or unable to&#xD;
             prevent conception during the trial period using contraceptive methods&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etsuro Hashimura</last_name>
    <role>Study Director</role>
    <affiliation>Kringle Pharma, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Etsuro Hashimura</last_name>
    <phone>+81-72-641-8739</phone>
    <email>hashimura@kringle-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saki Takimoto</last_name>
    <phone>+81-72-641-8739</phone>
    <email>takimoto@kringle-pharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kamigyo-ku</city>
        <state>Kyoto</state>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 16, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocyte Growth Factor</keyword>
  <keyword>HGF</keyword>
  <keyword>KP-100LI</keyword>
  <keyword>KP-100</keyword>
  <keyword>intracordal injection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

